智飞生物
(300122)
| 流通市值：187.11亿 | | | 总市值：316.70亿 |
| 流通股本：14.14亿 | | | 总股本：23.94亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,150,185,419.45 | 8,958,435,384.96 | 7,644,356,433.97 | 4,925,196,928.5 |
| 营业收入 | 2,150,185,419.45 | 8,958,435,384.96 | 7,644,356,433.97 | 4,925,196,928.5 |
| 二、营业总成本 | 2,218,602,295.96 | 12,358,235,775.89 | 8,826,798,368.98 | 5,355,146,772 |
| 营业成本 | 1,523,243,311.14 | 8,255,694,581.97 | 5,976,073,456.27 | 3,531,364,048.61 |
| 税金及附加 | 11,784,843.25 | 68,388,751.02 | 47,938,068.85 | 31,964,389.96 |
| 销售费用 | 293,704,514.71 | 2,386,453,403.38 | 1,618,372,119.71 | 1,048,962,015.25 |
| 管理费用 | 90,292,568.41 | 413,645,708.87 | 292,324,625.19 | 179,079,388.39 |
| 研发费用 | 213,682,660.68 | 932,298,240.66 | 668,694,285.13 | 419,057,232.21 |
| 财务费用 | 85,894,397.77 | 301,755,089.99 | 223,395,813.83 | 144,719,697.58 |
| 其中:利息费用 | 85,870,470.48 | 331,042,166.52 | 243,905,920.61 | 150,269,981.61 |
| 其中:利息收入 | 3,256,388.4 | 24,654,559.37 | 21,016,967.62 | 15,654,632.45 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | -14,221,154.72 | -7,777,347.26 | 2,355,610.36 |
| 加:投资收益 | -2,314,595.19 | 13,903.16 | 13,903.16 | - |
| 资产处置收益 | 3,107.74 | 5,880,932.83 | 5,818,931.18 | 5,815,453.17 |
| 资产减值损失(新) | -26,742,492.01 | -13,618,428,805.9 | -119,708,407.16 | -64,455,463.23 |
| 信用减值损失(新) | -353,558,778.64 | -509,730,029.51 | -379,631,251.55 | -318,630,355.34 |
| 其他收益 | 9,034,335.57 | 76,291,357.49 | 27,833,751.77 | 19,594,253.91 |
| 四、营业利润 | -441,995,299.04 | -17,459,994,187.58 | -1,655,892,354.87 | -785,270,344.63 |
| 加:营业外收入 | 650 | 113,677.12 | 97,369.65 | 22,562.32 |
| 减:营业外支出 | 2,911,009.63 | 32,781,880.29 | 1,322,706.32 | 1,086,203.24 |
| 五、利润总额 | -444,905,658.67 | -17,492,662,390.75 | -1,657,117,691.54 | -786,333,985.55 |
| 减:所得税费用 | -51,202,266.79 | -2,747,397,812.29 | -316,162,616.84 | -188,257,086.26 |
| 六、净利润 | -393,703,391.88 | -14,745,264,578.46 | -1,340,955,074.7 | -598,076,899.29 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -393,703,391.88 | -14,745,264,578.46 | -1,340,955,074.7 | -598,076,899.29 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -388,316,279 | -14,723,152,851.99 | -1,327,893,112.39 | -598,076,899.29 |
| 少数股东损益 | -5,387,112.88 | -22,111,726.47 | -13,061,962.31 | - |
| 扣除非经常损益后的净利润 | -391,344,217.71 | -14,743,796,350.21 | -1,348,223,662.39 | -620,830,015.28 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.16 | -6.15 | -0.55 | -0.25 |
| (二)稀释每股收益 | -0.16 | -6.15 | -0.55 | -0.25 |
| 九、综合收益总额 | -393,703,391.88 | -14,745,264,578.46 | -1,340,955,074.7 | -598,076,899.29 |
| 归属于母公司股东的综合收益总额 | -388,316,279 | -14,723,152,851.99 | -1,327,893,112.39 | -598,076,899.29 |
| 归属于少数股东的综合收益总额 | -5,387,112.88 | -22,111,726.47 | -13,061,962.31 | - |
| 公告日期 | 2026-04-28 | 2026-04-28 | 2025-10-30 | 2025-08-19 |
| 审计意见(境内) | | 标准无保留意见 | | |